NeoCore Technology Co., Ltd.
NeoCore Technology Co., Ltd. designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices. The company's products include food safety examination systems, human diagnosis arrays systems, agriculture examination systems, food examination arrays systems, and laboratory instruments, as well as DNA kits. It also offers laboratory planning, design, and other services. In addi… Read more
NeoCore Technology Co., Ltd. (4131) - Net Assets
Latest net assets as of September 2025: NT$316.30 Million TWD
Based on the latest financial reports, NeoCore Technology Co., Ltd. (4131) has net assets worth NT$316.30 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$555.16 Million) and total liabilities (NT$238.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$316.30 Million |
| % of Total Assets | 56.97% |
| Annual Growth Rate | 37.49% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 167.93 |
NeoCore Technology Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how NeoCore Technology Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NeoCore Technology Co., Ltd. (2021–2024)
The table below shows the annual net assets of NeoCore Technology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$305.09 Million | -13.15% |
| 2023-12-31 | NT$351.28 Million | +333.83% |
| 2022-12-31 | NT$80.97 Million | -31.00% |
| 2021-12-31 | NT$117.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NeoCore Technology Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14099700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$514.31 Million | 168.58% |
| Total Equity | NT$305.09 Million | 100.00% |
NeoCore Technology Co., Ltd. Competitors by Market Cap
The table below lists competitors of NeoCore Technology Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Skye Bioscience, Inc. Common Stock
NASDAQ:SKYE
|
$13.32 Million |
|
Plastiblends India Limited
NSE:PLASTIBLEN
|
$13.33 Million |
|
PRESSURE TECH.PLC LS -05
F:PRS
|
$13.34 Million |
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
$13.35 Million |
|
Philly Shipyard ASA
PINK:AKRRF
|
$13.32 Million |
|
Silver Viper Minerals Corp
OTCQB:VIPRF
|
$13.31 Million |
|
Silver Bullet Mines Corp.
OTCQB:SBMCF
|
$13.31 Million |
|
Enex Co.Ltd
KO:011090
|
$13.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeoCore Technology Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 347,676,000 to 305,086,000, a change of -42,590,000 (-12.2%).
- Net loss of 48,137,000 reduced equity.
- Other factors increased equity by 5,547,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-48.14 Million | -15.78% |
| Other Changes | NT$5.55 Million | +1.82% |
| Total Change | NT$- | -12.25% |
Book Value vs Market Value Analysis
This analysis compares NeoCore Technology Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.16x to 4.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$5.90 | NT$36.30 | x |
| 2022-12-31 | NT$4.00 | NT$36.30 | x |
| 2023-12-31 | NT$8.80 | NT$36.30 | x |
| 2024-12-31 | NT$7.72 | NT$36.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeoCore Technology Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -78.21%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.12x
- Recent ROE (-15.78%) is above the historical average (-21.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -15.35% | -19.34% | 0.32x | 2.52x | NT$-28.40 Million |
| 2022 | -37.16% | -31.71% | 0.33x | 3.51x | NT$-35.81 Million |
| 2023 | -18.59% | -99.87% | 0.12x | 1.58x | NT$-99.41 Million |
| 2024 | -15.78% | -78.21% | 0.18x | 1.12x | NT$-78.65 Million |
Industry Comparison
This section compares NeoCore Technology Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeoCore Technology Co., Ltd. (4131) | NT$316.30 Million | -15.35% | 0.76x | $13.32 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |